CNBC-TV18 accessed form 483 issued to Sun Pharmaceutical's Halol facility where the US drug regulator has issued 3 observations.
In an interview with CNBC-TV18, Vishal Manchanda of Nirmal Bang Institutional Equities spoke about the observations and gave his views on the stock.
We got the observations reviewed by a consultant and the opinion is largely that these are minor, so they can get through in a shorter timeframe, he said.
For full interview, watch accompanying video...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
